Portal de Periódicos da CAPES

Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis

2013; Elsevier BV; Volume: 11; Issue: 4 Linguagem: Inglês

10.1111/jth.12149

1538-7933

Trevor Baglin, Andreas Hillarp, Armando Tripodi, Ιsmail Εlalamy, Harry R. Büller, Walter Ageno,

Blood Coagulation and Thrombosis Mechanisms

Oral direct inhibitors (ODIs) of thrombin and factor Xa are now approved as anticoagulant drugs. The first two drugs to complete phase III clinical trials for thromboprophylaxis in orthopedic surgery and the treatment of patients with atrial fibrillation or venous thromboembolism (VTE) were dabigatran and rivaroxaban. These small molecules are given at fixed doses with no requirement for monitoring, as pharmacokinetic and pharmacodynamic responses are reliably predicted in patients with adequate renal function who are not taking other interacting drugs.